Summary of ISIS PHARMACEUTICALS INC

Quotes & Info

Enter Symbol(s):
e.g. YHOO, ^DJI

Symbol Lookup | Financial Search

ISIS > SEC Filings for ISIS > Form 8-K on 10-Dec-2012

All Recent SEC Filings

Show all filings for ISIS PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for ISIS PHARMACEUTICALS INC

10-Dec-2012

Entry into a Material Definitive Agreement, Financial Statements and Exh

Item 1.01. Entry into a Material Definitive Agreement.

On December 10, 2012, Isis Pharmaceuticals, Inc. ("Isis") and Biogen Idec announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.

Isis and Biogen Idec filed a press release describing this transaction. A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated December 10, 2012.

Add ISIS to Portfolio

Set Alert

Email to a Friend

Get SEC Filings for Another Symbol: Symbol Lookup

Quotes & Info for ISIS - All Recent SEC Filings

Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial Sign Up Now

Copyright © 2013 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.